80 related articles for article (PubMed ID: 24739801)
1. Can we identify response markers to antihypertensive drugs? First results from the IDEAL Trial.
Gueyffier F; Subtil F; Bejan-Angoulvant T; Zerbib Y; Baguet JP; Boivin JM; Mercier A; Leftheriotis G; Gagnol JP; Fauvel JP; Giraud C; Bricca G; Maucort-Boulch D; Erpeldinger S;
J Hum Hypertens; 2015 Jan; 29(1):22-7. PubMed ID: 24739801
[TBL] [Abstract][Full Text] [Related]
2. Blood pressure normalization by fixed perindopril/indapamide combination in hypertensive patients with or without associate metabolic syndrome: results of the OPTIMAX 2 study.
Mourad JJ; Lameira D; Guillausseau PJ
Vasc Health Risk Manag; 2008; 4(2):443-51. PubMed ID: 18561520
[TBL] [Abstract][Full Text] [Related]
3. Lowering blood pressure reduces renal events in type 2 diabetes.
de Galan BE; Perkovic V; Ninomiya T; Pillai A; Patel A; Cass A; Neal B; Poulter N; Harrap S; Mogensen CE; Cooper M; Marre M; Williams B; Hamet P; Mancia G; Woodward M; Glasziou P; Grobbee DE; MacMahon S; Chalmers J;
J Am Soc Nephrol; 2009 Apr; 20(4):883-92. PubMed ID: 19225038
[TBL] [Abstract][Full Text] [Related]
4. The Hypertension in the Very Elderly Trial - latest data.
Mukhtar O; Jackson SH
Br J Clin Pharmacol; 2013 Apr; 75(4):951-4. PubMed ID: 22897422
[TBL] [Abstract][Full Text] [Related]
5. Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure.
Teerlink JR; Diaz R; Felker GM; McMurray JJV; Metra M; Solomon SD; Adams KF; Anand I; Arias-Mendoza A; Biering-Sørensen T; Böhm M; Bonderman D; Cleland JGF; Corbalan R; Crespo-Leiro MG; Dahlström U; Echeverria LE; Fang JC; Filippatos G; Fonseca C; Goncalvesova E; Goudev AR; Howlett JG; Lanfear DE; Li J; Lund M; Macdonald P; Mareev V; Momomura SI; O'Meara E; Parkhomenko A; Ponikowski P; Ramires FJA; Serpytis P; Sliwa K; Spinar J; Suter TM; Tomcsanyi J; Vandekerckhove H; Vinereanu D; Voors AA; Yilmaz MB; Zannad F; Sharpsten L; Legg JC; Varin C; Honarpour N; Abbasi SA; Malik FI; Kurtz CE;
N Engl J Med; 2021 Jan; 384(2):105-116. PubMed ID: 33185990
[TBL] [Abstract][Full Text] [Related]
6. Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial.
Ruilope LM; Agarwal R; Anker SD; Bakris GL; Filippatos G; Nowack C; Kolkhof P; Joseph A; Mentenich N; Pitt B;
Am J Nephrol; 2019; 50(5):345-356. PubMed ID: 31665733
[TBL] [Abstract][Full Text] [Related]
7. Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial.
Bakris GL; Agarwal R; Anker SD; Pitt B; Ruilope LM; Nowack C; Kolkhof P; Ferreira AC; Schloemer P; Filippatos G; ;
Am J Nephrol; 2019; 50(5):333-344. PubMed ID: 31655812
[TBL] [Abstract][Full Text] [Related]
8. Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial.
Bhatt DL; Steg PG; Mehta SR; Leiter LA; Simon T; Fox K; Held C; Andersson M; Himmelmann A; Ridderstråle W; Chen J; Song Y; Diaz R; Goto S; James SK; Ray KK; Parkhomenko AN; Kosiborod MN; McGuire DK; Harrington RA;
Lancet; 2019 Sep; 394(10204):1169-1180. PubMed ID: 31484629
[TBL] [Abstract][Full Text] [Related]
9. Ticagrelor in Patients with Stable Coronary Disease and Diabetes.
Steg PG; Bhatt DL; Simon T; Fox K; Mehta SR; Harrington RA; Held C; Andersson M; Himmelmann A; Ridderstråle W; Leonsson-Zachrisson M; Liu Y; Opolski G; Zateyshchikov D; Ge J; Nicolau JC; Corbalán R; Cornel JH; Widimský P; Leiter LA;
N Engl J Med; 2019 Oct; 381(14):1309-1320. PubMed ID: 31475798
[TBL] [Abstract][Full Text] [Related]
10. Effects of Serelaxin in Patients with Acute Heart Failure.
Metra M; Teerlink JR; Cotter G; Davison BA; Felker GM; Filippatos G; Greenberg BH; Pang PS; Ponikowski P; Voors AA; Adams KF; Anker SD; Arias-Mendoza A; Avendaño P; Bacal F; Böhm M; Bortman G; Cleland JGF; Cohen-Solal A; Crespo-Leiro MG; Dorobantu M; Echeverría LE; Ferrari R; Goland S; Goncalvesová E; Goudev A; Køber L; Lema-Osores J; Levy PD; McDonald K; Manga P; Merkely B; Mueller C; Pieske B; Silva-Cardoso J; Špinar J; Squire I; Stępińska J; Van Mieghem W; von Lewinski D; Wikström G; Yilmaz MB; Hagner N; Holbro T; Hua TA; Sabarwal SV; Severin T; Szecsödy P; Gimpelewicz C;
N Engl J Med; 2019 Aug; 381(8):716-726. PubMed ID: 31433919
[TBL] [Abstract][Full Text] [Related]
11. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial.
Ray KK; Colhoun HM; Szarek M; Baccara-Dinet M; Bhatt DL; Bittner VA; Budaj AJ; Diaz R; Goodman SG; Hanotin C; Harrington RA; Jukema JW; Loizeau V; Lopes RD; Moryusef A; Murin J; Pordy R; Ristic AD; Roe MT; Tuñón J; White HD; Zeiher AM; Schwartz GG; Steg PG;
Lancet Diabetes Endocrinol; 2019 Aug; 7(8):618-628. PubMed ID: 31272931
[TBL] [Abstract][Full Text] [Related]
12. Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma.
Facon T; Kumar S; Plesner T; Orlowski RZ; Moreau P; Bahlis N; Basu S; Nahi H; Hulin C; Quach H; Goldschmidt H; O'Dwyer M; Perrot A; Venner CP; Weisel K; Mace JR; Raje N; Attal M; Tiab M; Macro M; Frenzel L; Leleu X; Ahmadi T; Chiu C; Wang J; Van Rampelbergh R; Uhlar CM; Kobos R; Qi M; Usmani SZ;
N Engl J Med; 2019 May; 380(22):2104-2115. PubMed ID: 31141632
[TBL] [Abstract][Full Text] [Related]
13. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome.
Schwartz GG; Steg PG; Szarek M; Bhatt DL; Bittner VA; Diaz R; Edelberg JM; Goodman SG; Hanotin C; Harrington RA; Jukema JW; Lecorps G; Mahaffey KW; Moryusef A; Pordy R; Quintero K; Roe MT; Sasiela WJ; Tamby JF; Tricoci P; White HD; Zeiher AM;
N Engl J Med; 2018 Nov; 379(22):2097-2107. PubMed ID: 30403574
[TBL] [Abstract][Full Text] [Related]
14. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease.
Ridker PM; Everett BM; Thuren T; MacFadyen JG; Chang WH; Ballantyne C; Fonseca F; Nicolau J; Koenig W; Anker SD; Kastelein JJP; Cornel JH; Pais P; Pella D; Genest J; Cifkova R; Lorenzatti A; Forster T; Kobalava Z; Vida-Simiti L; Flather M; Shimokawa H; Ogawa H; Dellborg M; Rossi PRF; Troquay RPT; Libby P; Glynn RJ;
N Engl J Med; 2017 Sep; 377(12):1119-1131. PubMed ID: 28845751
[TBL] [Abstract][Full Text] [Related]
15. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.
Neal B; Perkovic V; Mahaffey KW; de Zeeuw D; Fulcher G; Erondu N; Shaw W; Law G; Desai M; Matthews DR;
N Engl J Med; 2017 Aug; 377(7):644-657. PubMed ID: 28605608
[TBL] [Abstract][Full Text] [Related]
16. Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism.
Weitz JI; Lensing AWA; Prins MH; Bauersachs R; Beyer-Westendorf J; Bounameaux H; Brighton TA; Cohen AT; Davidson BL; Decousus H; Freitas MCS; Holberg G; Kakkar AK; Haskell L; van Bellen B; Pap AF; Berkowitz SD; Verhamme P; Wells PS; Prandoni P;
N Engl J Med; 2017 Mar; 376(13):1211-1222. PubMed ID: 28316279
[TBL] [Abstract][Full Text] [Related]
17. Renal function estimation and Cockroft-Gault formulas for predicting cardiovascular mortality in population-based, cardiovascular risk, heart failure and post-myocardial infarction cohorts: The Heart 'OMics' in AGEing (HOMAGE) and the high-risk myocardial infarction database initiatives.
Ferreira JP; Girerd N; Pellicori P; Duarte K; Girerd S; Pfeffer MA; McMurray JJ; Pitt B; Dickstein K; Jacobs L; Staessen JA; Butler J; Latini R; Masson S; Mebazaa A; Rocca HP; Delles C; Heymans S; Sattar N; Jukema JW; Cleland JG; Zannad F; Rossignol P;
BMC Med; 2016 Nov; 14(1):181. PubMed ID: 27829460
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of Presumably Disease Causing SCN1A Variants in a Cohort of Common Epilepsy Syndromes.
Lal D; Reinthaler EM; Dejanovic B; May P; Thiele H; Lehesjoki AE; Schwarz G; Riesch E; Ikram MA; van Duijn CM; Uitterlinden AG; Hofman A; Steinböck H; Gruber-Sedlmayr U; Neophytou B; Zara F; Hahn A; ; ; Gormley P; Becker F; Weber YG; Cilio MR; Kunz WS; Krause R; Zimprich F; Lemke JR; Nürnberg P; Sander T; Lerche H; Neubauer BA
PLoS One; 2016; 11(3):e0150426. PubMed ID: 26990884
[TBL] [Abstract][Full Text] [Related]
19. Polygenic scores for cardiovascular risk factors improve estimation of clinical outcomes in CCB treatment compared to pharmacogenetic variants alone.
Türkmen D; Bowden J; Masoli JAH; Delgado J; Kuo CL; Melzer D; Pilling LC
Pharmacogenomics J; 2024 Apr; 24(3):12. PubMed ID: 38632276
[TBL] [Abstract][Full Text] [Related]
20. Heterogeneity in Blood Pressure Response to 4 Antihypertensive Drugs: A Randomized Clinical Trial.
Sundström J; Lind L; Nowrouzi S; Hagström E; Held C; Lytsy P; Neal B; Marttala K; Östlund O
JAMA; 2023 Apr; 329(14):1160-1169. PubMed ID: 37039792
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
